Nidovirales infectious disease
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infections with viruses of the order nidovirales. The concept includes arterivirus infections and coronaviridae infections.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Nidovirales infectious disease
- Therapeutic area
- Infectious Disease
- Nidovirales infectious disease
- Nidovirales caused disease or disorder
- Nidovirales disease or disorder
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Unknown
- MONDO ID
- MONDO:0005876
- Parent condition
- MONDO:0100329
Related records
Broader conditions (7)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (7)
- Arterivirus infectious disease
- Coronaviridae infectious disease
- COVID-19
- Middle East respiratory syndrome
- Orthocoronavirinae infectious disease
- Severe acute respiratory syndrome
- Torovirus infectious disease
Trials (20)
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
- ACTIV-2: A Study for Outpatients With COVID-19
- ACTIV-3: Therapeutics for Inpatients With COVID-19
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
- Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
- EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
- Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
- Stellate Ganglion Block for COVID-induced Parosmia
- Vaccination for Recovered Inpatients With COVID-19 (VATICO)
- VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)